Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostic Services Program, has awarded coverage to the cancer profiling test GEM ExTra.
While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.
